Literature DB >> 22158627

Genomic promoter occupancy of runt-related transcription factor RUNX2 in Osteosarcoma cells identifies genes involved in cell adhesion and motility.

Margaretha van der Deen1, Jacqueline Akech, David Lapointe, Sneha Gupta, Daniel W Young, Martin A Montecino, Mario Galindo, Jane B Lian, Janet L Stein, Gary S Stein, Andre J van Wijnen.   

Abstract

Runt-related transcription factors (RUNX1, RUNX2, and RUNX3) are key lineage-specific regulators of progenitor cell growth and differentiation but also function pathologically as cancer genes that contribute to tumorigenesis. RUNX2 attenuates growth and stimulates maturation of osteoblasts during bone formation but is also robustly expressed in a subset of osteosarcomas, as well as in metastatic breast and prostate tumors. To assess the biological function of RUNX2 in osteosarcoma cells, we examined human genomic promoter interactions for RUNX2 using chromatin immunoprecipitation (ChIP)-microarray analysis in SAOS-2 cells. Promoter binding of both RUNX2 and RNA polymerase II was compared with gene expression profiles of cells in which RUNX2 was depleted by RNA interference. Many RUNX2-bound loci (1550 of 2339 total) exhibit promoter occupancy by RNA polymerase II and contain the RUNX consensus motif 5'-((T/A/C)G(T/A/C)GG(T/G). Gene ontology analysis indicates that RUNX2 controls components of multiple signaling pathways (e.g. WNT, TGFβ, TNFα, and interleukins), as well as genes linked to cell motility and adhesion (e.g. the focal adhesion-related genes FAK/PTK2 and TLN1). Our results reveal that siRNA depletion of RUNX2, PTK2, or TLN1 diminishes motility of U2OS osteosarcoma cells. Thus, RUNX2 binding to diverse gene loci may support the biological properties of osteosarcoma cells.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158627      PMCID: PMC3281617          DOI: 10.1074/jbc.M111.287771

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  79 in total

1.  Deletions of the RUNX2 gene are present in about 10% of individuals with cleidocranial dysplasia.

Authors:  Claus E Ott; Gundula Leschik; Fabienne Trotier; Louise Brueton; Han G Brunner; Wim Brussel; Encarna Guillen-Navarro; Claudia Haase; Juergen Kohlhase; Dieter Kotzot; Andrew Lane; Min Ae Lee-Kirsch; Susanne Morlot; Marleen E H Simon; Elisabeth Steichen-Gersdorf; David H Tegay; Hartmut Peters; Stefan Mundlos; Eva Klopocki
Journal:  Hum Mutat       Date:  2010-08       Impact factor: 4.878

2.  Comparison of sample preparation methods for ChIP-chip assays.

Authors:  Henriette O'Geen; Charles M Nicolet; Kim Blahnik; Roland Green; Peggy J Farnham
Journal:  Biotechniques       Date:  2006-11       Impact factor: 1.993

3.  Four novel RUNX2 mutations including a splice donor site result in the cleidocranial dysplasia phenotype.

Authors:  Hyo-Jin Kim; Soon-Hyeun Nam; Hyun-Jung Kim; Hyo-Sang Park; Hyun-Mo Ryoo; Shin-Yoon Kim; Tae-Joon Cho; Seung-Gon Kim; Suk-Chul Bae; In-San Kim; Janet L Stein; Andre J van Wijnen; Gary S Stein; Jane B Lian; Je-Yong Choi
Journal:  J Cell Physiol       Date:  2006-04       Impact factor: 6.384

4.  Runx regulation of sphingolipid metabolism and survival signaling.

Authors:  Anna Kilbey; Anne Terry; Alma Jenkins; Gillian Borland; Qifeng Zhang; Michael J O Wakelam; Ewan R Cameron; James C Neil
Journal:  Cancer Res       Date:  2010-06-29       Impact factor: 12.701

Review 5.  Metastatic bone disease: role of transcription factors and future targets.

Authors:  Jitesh Pratap; Jane B Lian; Gary S Stein
Journal:  Bone       Date:  2010-06-01       Impact factor: 4.398

6.  Expression analysis of genes associated with human osteosarcoma tumors shows correlation of RUNX2 overexpression with poor response to chemotherapy.

Authors:  Bekim Sadikovic; Paul Thorner; Susan Chilton-Macneill; Jeff W Martin; Nilva K Cervigne; Jeremy Squire; Maria Zielenska
Journal:  BMC Cancer       Date:  2010-05-13       Impact factor: 4.430

7.  Motif Enrichment Analysis: a unified framework and an evaluation on ChIP data.

Authors:  Robert C McLeay; Timothy L Bailey
Journal:  BMC Bioinformatics       Date:  2010-04-01       Impact factor: 3.169

8.  Runx2 transcriptome of prostate cancer cells: insights into invasiveness and bone metastasis.

Authors:  Sanjeev K Baniwal; Omar Khalid; Yankel Gabet; Ruchir R Shah; Daniel J Purcell; Deepak Mav; Alice E Kohn-Gabet; Yunfan Shi; Gerhard A Coetzee; Baruch Frenkel
Journal:  Mol Cancer       Date:  2010-09-23       Impact factor: 27.401

9.  Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.

Authors:  Karen Blyth; François Vaillant; Linda Hanlon; Nancy Mackay; Margaret Bell; Alma Jenkins; James C Neil; Ewan R Cameron
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

10.  Cancer-related ectopic expression of the bone-related transcription factor RUNX2 in non-osseous metastatic tumor cells is linked to cell proliferation and motility.

Authors:  David T Leong; Joleen Lim; Xuewei Goh; Jitesh Pratap; Barry P Pereira; Hui Si Kwok; Saminathan Suresh Nathan; Jason R Dobson; Jane B Lian; Yoshiaki Ito; P Mathijs Voorhoeve; Gary S Stein; Manuel Salto-Tellez; Simon M Cool; Andre J van Wijnen
Journal:  Breast Cancer Res       Date:  2010-10-28       Impact factor: 6.466

View more
  45 in total

1.  Research findings working with the p53 and Rb1 targeted osteosarcoma mouse model.

Authors:  Yaojuan Lu; Steven Gitelis; Guanghua Lei; Ming Ding; Carl Maki; Ranim R Mira; Qiping Zheng
Journal:  Am J Cancer Res       Date:  2014-05-26       Impact factor: 6.166

Review 2.  Epigenetic pathways regulating bone homeostasis: potential targeting for intervention of skeletal disorders.

Authors:  Jonathan A R Gordon; Martin A Montecino; Rami I Aqeilan; Janet L Stein; Gary S Stein; Jane B Lian
Journal:  Curr Osteoporos Rep       Date:  2014-12       Impact factor: 5.096

3.  Extracellular vesicles from osteosarcoma cell lines contain miRNAs associated with cell adhesion and apoptosis.

Authors:  Sofía Jerez; Héctor Araya; Daniel Hevia; Carlos E Irarrázaval; Roman Thaler; Andre J van Wijnen; Mario Galindo
Journal:  Gene       Date:  2019-06-06       Impact factor: 3.688

4.  Expression of the ectodomain-releasing protease ADAM17 is directly regulated by the osteosarcoma and bone-related transcription factor RUNX2.

Authors:  Héctor F Araya; Hugo Sepulveda; Carlos O Lizama; Oscar A Vega; Sofia Jerez; Pedro F Briceño; Roman Thaler; Scott M Riester; Marcelo Antonelli; Flavio Salazar-Onfray; Juan Pablo Rodríguez; Ricardo D Moreno; Martin Montecino; Martine Charbonneau; Claire M Dubois; Gary S Stein; Andre J van Wijnen; Mario A Galindo
Journal:  J Cell Biochem       Date:  2018-06-19       Impact factor: 4.429

5.  The RUNX2 cistrome in osteoblasts: characterization, down-regulation following differentiation, and relationship to gene expression.

Authors:  Mark B Meyer; Nancy A Benkusky; J Wesley Pike
Journal:  J Biol Chem       Date:  2014-04-24       Impact factor: 5.157

6.  Hypoxia-related microRNA-210 is a diagnostic marker for discriminating osteoblastoma and osteosarcoma.

Authors:  Scott M Riester; Jorge Torres-Mora; Amel Dudakovic; Emily T Camilleri; Wei Wang; Fuhua Xu; Roman R Thaler; Jared M Evans; René Zwartbol; Inge H Briaire-de Bruijn; Avudaiappan Maran; Andrew L Folpe; Carrie Y Inwards; Peter S Rose; Thomas C Shives; Michael J Yaszemski; Franklin H Sim; David R Deyle; Annalise N Larson; Mario A Galindo; Arjen G H Cleven; Andre M Oliveira; Anne-Marie Cleton-Jansen; Judith V M G Bovée; Andre J van Wijnen
Journal:  J Orthop Res       Date:  2016-06-28       Impact factor: 3.494

7.  RUNX2 is overexpressed in melanoma cells and mediates their migration and invasion.

Authors:  Rajeev K Boregowda; Oyenike O Olabisi; Walid Abushahba; Byeong-Seon Jeong; Keneshia K Haenssen; Wenjin Chen; Marina Chekmareva; Ahmed Lasfar; David J Foran; James S Goydos; Karine A Cohen-Solal
Journal:  Cancer Lett       Date:  2014-03-18       Impact factor: 8.679

8.  LINE-1 expression and retrotransposition in Barrett's esophagus and esophageal carcinoma.

Authors:  Tara T Doucet-O'Hare; Nemanja Rodić; Reema Sharma; Isha Darbari; Gabriela Abril; Jungbin A Choi; Ji Young Ahn; Yulan Cheng; Robert A Anders; Kathleen H Burns; Stephen J Meltzer; Haig H Kazazian
Journal:  Proc Natl Acad Sci U S A       Date:  2015-08-17       Impact factor: 11.205

9.  Clinical significance of RUNX2 expression in patients with nonsmall cell lung cancer: a 5-year follow-up study.

Authors:  Hong Li; Ren-Jie Zhou; Guo-Qiang Zhang; Jian-Ping Xu
Journal:  Tumour Biol       Date:  2013-03-08

Review 10.  The RUNX family in breast cancer: relationships with estrogen signaling.

Authors:  N-O Chimge; B Frenkel
Journal:  Oncogene       Date:  2012-10-08       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.